Skip to main content
Article
Licensed
Unlicensed Requires Authentication

Intestinal permeability in patients with metastatic colon cancer treated with patupilone

  • , , , , , , , and EMAIL logo
Published/Copyright: June 17, 2014
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 52 Issue 11

Abstract

Background: Only a limited number of cytotoxic drugs have shown activity in metastatic colorectal carcinoma. Patupilone is a novel agent with promising activity in this common cancer. Diarrhea represents the dose-limiting toxicity of patupilone. Measurement of intestinal permeability is one of the potential methods of non-invasive laboratory assessment of gastrointestinal toxicity.

Methods: We have assessed intestinal permeability by measuring absorption of lactulose, mannitol and xylose in 27 previously treated patients with metastatic colorectal cancer enrolled in a phase I trial of patupilone.

Results: Lactulose/mannitol and lactulose/xylose ratios increased after the treatment. Significantly higher lactulose/mannitol ratio was observed in patients who had severe diarrhea. Moreover, patients who subsequently had an adverse event of grade 3 or higher had significantly higher baseline lactulose/mannitol or lactulose/xylose ratios.

Conclusions: Measurement of intestinal permeability using the lactulose/mannitol test may represent a biomarker for the monitoring, or even prediction of toxicity of cytotoxic drugs, including patupilone.

Keywords: colorectal cancer; intestinal permeability; patupilone
Corresponding author: Martin Doležel, MD, PhD, Department of Oncology, Palacký University Medical School and Teaching Hospital, I.P. Pavlova 6, 775 20 Olomouc, Czech Republic, Phone: +420 588444288, Fax: +420 588442522, E-mail:

Acknowledgments

Supported by the Research Project Biomedreg CZ.1.05/2.1.00/01.0030, project of the Palacký University LF_2013_010, and the project of the Ministry of Health of the Czech Republic for conceptual development of research organizations 00179906. The trial of patupilone was conducted by Novartis.

Conflict of interest statement

Authors’ conflict of interest disclosure: The authors stated that there are no conflicts of interest regarding the publication of this article. Research support played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: Bohuslav Melichar has received honoraria for speeches and advisory role from Novartis. Michaela Zezulová has received honororia for speeches from Novartis.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.10.3322/caac.20107Search in Google Scholar

2. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Expectancy or primary chemotherapy in patients with advanced colorectal cancer: a randomized trial. J Clin Oncol 1992;10:904–11.10.1200/JCO.1992.10.6.904Search in Google Scholar

3. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, et al. Irinotecan combined with fluorouracil com pared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041–7.10.1016/S0140-6736(00)02034-1Search in Google Scholar

4. Tournigand C, Andre T, Achille E, Lledo G, Flesch M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–37.10.1200/JCO.2004.05.113Search in Google Scholar

5. Hurwitz H, Febrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.10.1056/NEJMoa032691Search in Google Scholar

6. Jonker DJ, O Callaghan CJ, Karapetis C, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040–8.10.1056/NEJMoa071834Search in Google Scholar

7. Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, et al. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 2011;105:1646–53.10.1038/bjc.2011.438Search in Google Scholar

8. Hussain A, DiPaola RS, Baron AD, Higano CS, Tchekmedyian NS, Johri AR. Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer. Ann Oncol 2009;20:492–7.10.1093/annonc/mdn665Search in Google Scholar

9. ten Bokkel Huinink WW, Sufliarsky J, Smit WM, Spanik S, Wagnarova M, Hirte HW, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol 2009;27:3097–103.10.1200/JCO.2008.20.4826Search in Google Scholar

10. Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, et al. Management of cancer treatment-related diarrhea: issues and therapeutic strategies. J Pain Symptom Manage 2000;19:118–29.10.1016/S0885-3924(99)00149-9Search in Google Scholar

11. Gibson RJ, Keefe MK, Lalla RV, Bateman E, Blijlevens N, Fijlstra M, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013;21:313–26.10.1007/s00520-012-1644-zSearch in Google Scholar

12. Stringer AM, Al-Dasooqi N, Bowen JM, Tan TH, Radzuan M, Logan RM, et al. Biomarkers of chemotherapy-induced diarrhoea: a clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 2013;21:1843–52.10.1007/s00520-013-1741-7Search in Google Scholar

13. Lalla RV, Ashbury FD. The MASCC/ISOO mucositis guidelines: dissemination and clinical impact. Support Care Cancer 2013;21:3161–3.10.1007/s00520-013-1924-2Search in Google Scholar

14. Bjarnason I, Macpherson A, Hollander D. Intestinal permeability: an overview. Gastroenterology 1995;1995:1566–81.10.1016/0016-5085(95)90708-4Search in Google Scholar

15. Uil JJ, van Elburg RM, van Overbeek FM, Mulder CJ, van Berge-Henegouwen GP, Heymans HS. Clinical implications of the sugar absorption test: intestinal permeability test to assess mucosal barrier function. Scand J Gastroenterol 1997;32:70–8.Search in Google Scholar

16. DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J Clin Gastroenterol 2002;34:385–96.10.1097/00004836-200204000-00003Search in Google Scholar PubMed

17. Melichar B, Kohout P, Bratova M, Solichova D, Kralickova P, Zadak Z. Intestinal permeability in patients with chemotherapy-induced stomatitis. J Cancer Res Clin Oncol 2001;127:314–8.10.1007/s004320000209Search in Google Scholar PubMed

18. Melichar B, Dvorak J, Hyspler R, Zadak Z. Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy 2005;51:336–8.10.1159/000088957Search in Google Scholar PubMed

19. Melichar B, Dvorak J, Krcmova L, Hyspler R, Urbánek L, Solichova D. Intestinal permeability and vitamin A absoption in patients with chemotherapy-induced diarrhea. Am J Clin Oncol 2008;31:580–4.10.1097/COC.0b013e318174dbb9Search in Google Scholar PubMed

20. Melichar B. Laboratory medicine and medical oncology: the tale of two Cinderellas. Clin Chem Lab Med 2013;51:99–112.10.1515/cclm-2012-0496Search in Google Scholar PubMed

21. Cardinale D, Salvatici M, Sandri MT. Role of biomarkers in cardioncology. Clin Chem Lab Med 2011;49:1937–48.10.1515/CCLM.2011.692Search in Google Scholar PubMed

22. Carneiro-Filho BA, Lima IP, Araujo DH, Cavalcante MC, Carvalho GH, Brito GA, et al. Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Digest Dis Sci 2004;49:65–72.10.1023/B:DDAS.0000011604.45531.2cSearch in Google Scholar

23. Yanez JA, Teng XW, Roupe KA, Fariss MW, Davies NM. Chemotherapy induced gastrointestinal toxicity in rats: involvement of mitochondrial DNA, gastrointestinal permeability and cyclooxygenase-2. J Pharm Pharmaceut Sci 2003;6:308–14.Search in Google Scholar

24. Parrilli G, Iaffaioli RV, Capuano G, Budillon G, Bianco AR. Changes in intestinal permeability to lactulose by cytotoxic chemotherapy. Cancer Treat Rep 1982;66:1435–6.Search in Google Scholar

25. Parrilli G, Iaffaioli RV, Martorano M, Cuomo R, Tafuto S, Zampino MG, et al. Effects of anthracycline therapy on intestinal absorption in patients with advanced breast cancer. Cancer Res 1989;49:3689–91.Search in Google Scholar

26. Kohout P, Cerman J, Bratova M, Zadak Z. Small bowel permeability in patients with cytostatic therapy. Nutrition 1999;15:546–9.10.1016/S0899-9007(99)00113-6Search in Google Scholar

27. Daniele B, Secondulfo M, De Vivo R, Pignata S, De Magistris L, Delrio P, et al. Effect of chemotherapy with 5-fluorouracil on intestinal permeability and absorption in patients with advanced colorectal cancer. J Clin Gastroenterol 2001;32:228–30.10.1097/00004836-200103000-00010Search in Google Scholar PubMed

28. Russo F, Linsalata M, Clemente C, D’Attoma B, Orlando A, Campanella G, et al. The effect of fluorouracil, epirubicin, and cyclophosphamide (FEC60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer 2013;13:56.10.1186/1471-2407-13-56Search in Google Scholar PubMed PubMed Central

29. Bow EJ, Loewen R, Cheang MS, Shore TB, Rubinger M, Schacter B. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997;15:2254–61.10.1200/JCO.1997.15.6.2254Search in Google Scholar PubMed

30. Sundstrom GM, Wahlin A, Nordin-Anderson I, Suhr OB. Intestinal permeability in patients with acute myeloid leukemia. Eur J Haematol 1998;61:250–4.10.1111/j.1600-0609.1998.tb01710.xSearch in Google Scholar PubMed

31. Gibson RJ, Gummins AG, Bowen JM, Logan RM, Healey T, Keefe DM. Apoptosis occurs early in the basal layer of the oral mucosa following cancer chemotherapy. Asia Pac J Clin Oncol 2006;2:39–49.10.1111/j.1743-7563.2006.00038.xSearch in Google Scholar

Received: 2014-1-27
Accepted: 2014-5-19
Published Online: 2014-6-17
Published in Print: 2014-11-19

©2014 by De Gruyter

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. From symptoms to biomarkers: a change of paradigm
  4. Reviews
  5. Biochemical markers in early diagnosis and management of systemic amyloidoses
  6. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis
  7. Genetics and Molecular Diagnostics
  8. Selection of an optimal method for co-isolation of circulating DNA and miRNA from the plasma of pregnant women
  9. General Clinical Chemistry and Laboratory Medicine
  10. Harmonisation of seven common enzyme results through EQA
  11. Harmonization in hemolysis detection and prevention. A working group of the Catalonian Health Institute (ICS) experience
  12. Adopting European Network for Health Technology Assessments (EunetHTA) core model for diagnostic technologies for improving the accuracy and appropriateness of blood gas analyzers’ assessment
  13. Impact of assay design on test performance: lessons learned from 25-hydroxyvitamin D
  14. Anti-ruthenium antibodies mimic macro-TSH in electrochemiluminescent immunoassay
  15. The relationship between the Spine Deformity Index, biochemical parameters of bone metabolism and vascular calcifications: results from the Epidemiological VERtebral FRACtures iTalian Study (EVERFRACT) in dialysis patients
  16. Quantification of polyclonal free light chains in clinical samples using a single turbidimetric immunoassay
  17. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate
  18. Reference Values and Biological Variations
  19. The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer
  20. The quality of diagnostic testing may be impaired during shipment of lithium-heparin gel tubes
  21. Cancer Diagnostics
  22. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer
  23. Intestinal permeability in patients with metastatic colon cancer treated with patupilone
  24. Cardiovascular Diseases
  25. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay
  26. Infectious Diseases
  27. Early indicators of severity and construction of a risk model for prognosis based upon laboratory parameters in patients with hemorrhagic fever with renal syndrome
  28. Corrigendum
  29. Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation
  30. Letters to the Editor
  31. The future of the laboratory information system – what are the requirements for a powerful system for a laboratory data management?
  32. Hypernatraemia in disguise
  33. Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins
  34. The impact of exercise on the variation of serum free light chains
  35. Response to Jacobs: N Latex FLC serum free light-chain assays in patients with renal impairment
  36. Reply to Berlanga et al. (DOI 10.1515/cclm-2014-0420)
  37. Mean platelet volume in patients with non-alcoholic fatty liver disease: is mean platelet volume ready as a surrogate marker?
  38. False-positive D-dimer result in a latex-enhanced immunoassay caused by interfering human anti-mouse antibodies
  39. D-Dimer in normal pregnancy: determination of reference values for three commercially available assays
  40. Paraoxonase 2 sequence variation (c.311 C>G) is associated with a modest decrease in circulating LDL size in children and adolescents
  41. The effect of volume of hydrochloric acid preservation on 24-hour urinary catecholamine test
  42. Congress Abstracts
  43. Congress of Clinical Chemistry and Laboratory Medicine
  44. The 3rd EFLM-UEMS Congress
  45. 46th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine)
https://doi.org/10.1515/cclm-2014-0096
Keywords for this article
colorectal cancer; intestinal permeability; patupilone

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. From symptoms to biomarkers: a change of paradigm
  4. Reviews
  5. Biochemical markers in early diagnosis and management of systemic amyloidoses
  6. The accuracy of the anti-mitochondrial antibody and the M2 subtype test for diagnosis of primary biliary cirrhosis: a meta-analysis
  7. Genetics and Molecular Diagnostics
  8. Selection of an optimal method for co-isolation of circulating DNA and miRNA from the plasma of pregnant women
  9. General Clinical Chemistry and Laboratory Medicine
  10. Harmonisation of seven common enzyme results through EQA
  11. Harmonization in hemolysis detection and prevention. A working group of the Catalonian Health Institute (ICS) experience
  12. Adopting European Network for Health Technology Assessments (EunetHTA) core model for diagnostic technologies for improving the accuracy and appropriateness of blood gas analyzers’ assessment
  13. Impact of assay design on test performance: lessons learned from 25-hydroxyvitamin D
  14. Anti-ruthenium antibodies mimic macro-TSH in electrochemiluminescent immunoassay
  15. The relationship between the Spine Deformity Index, biochemical parameters of bone metabolism and vascular calcifications: results from the Epidemiological VERtebral FRACtures iTalian Study (EVERFRACT) in dialysis patients
  16. Quantification of polyclonal free light chains in clinical samples using a single turbidimetric immunoassay
  17. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate
  18. Reference Values and Biological Variations
  19. The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer
  20. The quality of diagnostic testing may be impaired during shipment of lithium-heparin gel tubes
  21. Cancer Diagnostics
  22. Serum human epididymis protein 4 (HE4) as a tumor marker in men with lung cancer
  23. Intestinal permeability in patients with metastatic colon cancer treated with patupilone
  24. Cardiovascular Diseases
  25. European multicenter analytical evaluation of the Abbott ARCHITECT STAT high sensitive troponin I immunoassay
  26. Infectious Diseases
  27. Early indicators of severity and construction of a risk model for prognosis based upon laboratory parameters in patients with hemorrhagic fever with renal syndrome
  28. Corrigendum
  29. Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation
  30. Letters to the Editor
  31. The future of the laboratory information system – what are the requirements for a powerful system for a laboratory data management?
  32. Hypernatraemia in disguise
  33. Interference of therapeutic monoclonal immunoglobulins in the investigation of M-proteins
  34. The impact of exercise on the variation of serum free light chains
  35. Response to Jacobs: N Latex FLC serum free light-chain assays in patients with renal impairment
  36. Reply to Berlanga et al. (DOI 10.1515/cclm-2014-0420)
  37. Mean platelet volume in patients with non-alcoholic fatty liver disease: is mean platelet volume ready as a surrogate marker?
  38. False-positive D-dimer result in a latex-enhanced immunoassay caused by interfering human anti-mouse antibodies
  39. D-Dimer in normal pregnancy: determination of reference values for three commercially available assays
  40. Paraoxonase 2 sequence variation (c.311 C>G) is associated with a modest decrease in circulating LDL size in children and adolescents
  41. The effect of volume of hydrochloric acid preservation on 24-hour urinary catecholamine test
  42. Congress Abstracts
  43. Congress of Clinical Chemistry and Laboratory Medicine
  44. The 3rd EFLM-UEMS Congress
  45. 46th National Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC – Laboratory Medicine)
Downloaded on 24.4.2026 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2014-0096/html?lang=en
Scroll to top button